Search

Your search keyword '"Vivian Rotman"' showing total 2 results
Start Over Author "Vivian Rotman" Publisher mdpi ag
2 results on '"Vivian Rotman"'

1. Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports

Author

Vanessa D. Costa, Patricia Pellegrini, Vivian Rotman, Ana Maria Pittella, Estevão P. Nunes, Barbara V. Lago, Elisabeth Lampe, and Francisco C. A. Mello

Subjects
hepatitis c virus (hcv), daa, resistance, Microbiology, QR1-502
Abstract

In Brazil, hepatitis C treatment has been evolving significantly with the licensing of direct-acting antivirals (DAAs). However, viral determinants (amino acid substitutions in hepatitis C virus (HCV) genome and infective genotype) associated with host factors (hepatic condition and prior HCV therapy) might limit the achievement of sustained virologic response (SVR). Here, we described two case reports in which the occurrence of HCV NS5A mutations A30K (subtype 3a) and Y93N (subtype 1a) might have influenced daclatasvir (DCV)/sofosbuvir (SOF) combined therapy non-response. Despite high response rates for DAA combined therapies in Brazil, these case reports stated the importance of an investigation about how to manage a DAA treatment failure since a combination of factors, especially the occurrence of resistance substitutions, could impact a rescue therapy with new available antivirals in clinical routine.

Published
2019
Full Text
View/download PDF

2. Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports

Author

Ana Maria Pittella, Francisco C. A. Mello, Barbara Vieira do Lago, Patricia Pellegrini, Vanessa Duarte da Costa, Vivian Rotman, Estevão Portela Nunes, and Elisabeth Lampe

Subjects
Male, Pyrrolidines, Daclatasvir, Sofosbuvir, Hepatitis C virus, lcsh:QR1-502, Hepacivirus, Viral Nonstructural Proteins, medicine.disease_cause, Antiviral Agents, lcsh:Microbiology, Treatment failure, resistance, Rescue therapy, Virology, Drug Resistance, Viral, Genotype, medicine, Humans, Treatment Failure, NS5A, DAA, Aged, business.industry, Communication, Imidazoles, Valine, Hepatitis C, Hepatitis C, Chronic, medicine.disease, Infectious Diseases, Mutation, Female, Carbamates, business, hepatitis C virus (HCV), medicine.drug
Abstract

In Brazil, hepatitis C treatment has been evolving significantly with the licensing of direct-acting antivirals (DAAs). However, viral determinants (amino acid substitutions in hepatitis C virus (HCV) genome and infective genotype) associated with host factors (hepatic condition and prior HCV therapy) might limit the achievement of sustained virologic response (SVR). Here, we described two case reports in which the occurrence of HCV NS5A mutations A30K (subtype 3a) and Y93N (subtype 1a) might have influenced daclatasvir (DCV)/sofosbuvir (SOF) combined therapy non-response. Despite high response rates for DAA combined therapies in Brazil, these case reports stated the importance of an investigation about how to manage a DAA treatment failure since a combination of factors, especially the occurrence of resistance substitutions, could impact a rescue therapy with new available antivirals in clinical routine.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results